Published in APMIS on October 06, 2008
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest (2010) 3.41
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res (2011) 2.54
Does tumour dormancy offer a therapeutic target? Nat Rev Cancer (2010) 2.19
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer (2010) 2.13
Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res (2010) 1.95
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res (2009) 1.69
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V. J Clin Oncol (2016) 1.54
EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol (2010) 1.52
ERK1/2 and p38α/β signaling in tumor cell quiescence: opportunities to control dormant residual disease. Clin Cancer Res (2011) 1.44
Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer (2013) 1.40
Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27
Dormancy of metastatic melanoma. Pigment Cell Melanoma Res (2009) 1.19
Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res (2009) 1.18
Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res (2013) 1.15
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med (2013) 1.07
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med (2009) 1.07
GAS6 receptor status is associated with dormancy and bone metastatic tumor formation. PLoS One (2013) 1.06
The tumor microenvironment: the making of a paradigm. Cancer Microenviron (2009) 1.06
Squamous cell carcinoma of the oral cavity and circulating tumour cells. World J Clin Oncol (2014) 1.02
Decoding melanoma metastasis. Cancers (Basel) (2010) 1.02
Microenvironments dictating tumor cell dormancy. Recent Results Cancer Res (2012) 1.01
TBK1 regulates prostate cancer dormancy through mTOR inhibition. Neoplasia (2013) 1.01
Biology and significance of circulating and disseminated tumour cells in colorectal cancer. Langenbecks Arch Surg (2012) 1.01
DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med (2012) 1.01
Regulation of tumor cell dormancy by tissue microenvironments and autophagy. Adv Exp Med Biol (2013) 1.00
Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol (2011) 0.97
Computer aided identification of small molecules disrupting uPAR/alpha5beta1--integrin interaction: a new paradigm for metastasis prevention. PLoS One (2009) 0.93
Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res (2010) 0.91
Prospective identification of glioblastoma cells generating dormant tumors. PLoS One (2012) 0.90
MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer (2011) 0.89
A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients. PLoS One (2012) 0.89
Dormancy in breast cancer. Breast Cancer (Dove Med Press) (2012) 0.89
Single cell transcriptomic analysis of prostate cancer cells. BMC Mol Biol (2013) 0.89
Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol (2013) 0.88
The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes Cancer (2012) 0.88
The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. Front Oncol (2014) 0.87
Cancer Metastases: Early Dissemination and Late Recurrences. Cancer Growth Metastasis (2015) 0.86
Molecular alterations associated with osteosarcoma development. Sarcoma (2012) 0.86
PTHrP induces autocrine/paracrine proliferation of bone tumor cells through inhibition of apoptosis. PLoS One (2011) 0.85
Quantum dot loaded immunomicelles for tumor imaging. BMC Med Imaging (2010) 0.81
Prognostic relevance of minimal residual disease in colorectal cancer. World J Gastroenterol (2014) 0.81
TLR4 ligand/H₂O₂ enhances TGF-β1 signaling to induce metastatic potential of non-invasive breast cancer cells by activating non-Smad pathways. PLoS One (2013) 0.80
Investigating breast cancer cell behavior using tissue engineering scaffolds. PLoS One (2015) 0.79
Platelet proteome and tumor dormancy: can platelets content serve as predictive biomarkers for exit of tumors from dormancy? Cancers (Basel) (2010) 0.79
Prostate cancer xenografts engineered from 3D precision-porous poly(2-hydroxyethyl methacrylate) hydrogels as models for tumorigenesis and dormancy escape. Biomaterials (2014) 0.78
Cancer-immune equilibrium: questions unanswered. Cancer Microenviron (2011) 0.78
Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis (2016) 0.77
FXR1a-associated microRNP: a driver of specialized non-canonical translation in quiescent conditions. RNA Biol (2016) 0.75
Intravital imaging of the effects of 5-fluorouracil on the murine liver microenvironment using 2-photon laser scanning microscopy. Oncol Lett (2016) 0.75
Mathematical models of breast and ovarian cancers. Wiley Interdiscip Rev Syst Biol Med (2016) 0.75
PHOX2B is a suppressor of neuroblastoma metastasis. Oncotarget (2016) 0.75
Biological and molecular aspects of lymph node metastasis in gastro-intestinal cancer. Int J Clin Oncol (2013) 0.75
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res (2007) 6.59
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol (2013) 4.11
Circulating tumor cells: liquid biopsy of cancer. Clin Chem (2012) 3.87
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23
Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res (2010) 2.98
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74
Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer (2008) 2.72
Tumor metastasis: moving new biological insights into the clinic. Nat Med (2013) 2.71
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res (2010) 2.66
Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res (2013) 2.50
HIF induces human embryonic stem cell markers in cancer cells. Cancer Res (2011) 2.46
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Circulating tumor cells and circulating tumor DNA. Annu Rev Med (2011) 2.16
HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial. Breast Cancer Res Treat (2010) 2.12
Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res (2005) 2.10
Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell (2013) 2.08
Circulating tumor cells and bone marrow micrometastasis. Clin Cancer Res (2008) 2.06
Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med (2012) 2.00
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res (2005) 1.82
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res (2012) 1.79
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Controversies in clinical cancer dormancy. Proc Natl Acad Sci U S A (2011) 1.71
Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res (2012) 1.63
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60
Circulating tumor cell isolation and diagnostics: toward routine clinical use. Cancer Res (2011) 1.58
Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56
Biologic challenges in the detection of circulating tumor cells. Cancer Res (2012) 1.55
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Rare expression of epithelial cell adhesion molecule on residual micrometastatic breast cancer cells after adjuvant chemotherapy. Clin Cancer Res (2003) 1.53
Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res (2006) 1.52
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res (2009) 1.50
Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther (2007) 1.50
Plasticity of disseminating cancer cells in patients with epithelial malignancies. Cancer Metastasis Rev (2012) 1.47
Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization. Pathobiology (2008) 1.47
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res (2006) 1.47
Genomic profiling of viable and proliferative micrometastatic cells from early-stage breast cancer patients. Clin Cancer Res (2004) 1.40
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer (2002) 1.35
Clinical relevance and biology of circulating tumor cells. Breast Cancer Res (2011) 1.34
Down-regulated expression of cytokeratin 18 promotes progression of human breast cancer. Clin Cancer Res (2004) 1.33
Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res (2004) 1.31
Changes in keratin expression during metastatic progression of breast cancer: impact on the detection of circulating tumor cells. Clin Cancer Res (2012) 1.30
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem (2007) 1.28
Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. Int J Cancer (2013) 1.27
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
High-resolution genomic profiling of occult micrometastatic tumor cells. Genes Chromosomes Cancer (2003) 1.25
Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer. Breast Cancer Res (2009) 1.25
Circulating tumors cells as biomarkers: progress toward biomarker qualification. Cancer J (2011) 1.25
Technologies for detection of circulating tumor cells: facts and vision. Lab Chip (2013) 1.24
Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer (2013) 1.23
Circulating tumor cells as therapy-related biomarkers in cancer patients. Cancer Immunol Immunother (2013) 1.23
Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int (2010) 1.22
Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. Mol Oncol (2011) 1.21
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study. Breast Cancer Res (2012) 1.21
Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res (2012) 1.20
Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions. Mod Pathol (2013) 1.19
Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood (2013) 1.19
Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res (2009) 1.19
Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res (2002) 1.19
Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer (2003) 1.18
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer. Oncotarget (2013) 1.17
Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer. Ann N Y Acad Sci (2008) 1.17
Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol (2012) 1.16
Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat (2012) 1.16
Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One (2013) 1.16
Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci (2010) 1.15
Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci U S A (2002) 1.15
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. Prostate (2011) 1.13
Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods (2005) 1.13
Regulation of estrogen-dependent transcription by the LIM cofactors CLIM and RLIM in breast cancer. Cancer Res (2009) 1.12
Detection and measurement of occult disease for the prognosis of solid tumors. J Clin Oncol (2003) 1.11
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat (2012) 1.11
L1 is associated with micrometastatic spread and poor outcome in colorectal cancer. Mod Pathol (2007) 1.10
Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clin Chem (2013) 1.10
Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat (2010) 1.09
Capture of viable circulating tumor cells in the liver of colorectal cancer patients. Clin Chem (2013) 1.09
Micrometastatic spread in breast cancer: detection, molecular characterization and clinical relevance. Breast Cancer Res (2008) 1.09
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08
Distinct functional roles of Akt isoforms for proliferation, survival, migration and EGF-mediated signalling in lung cancer derived disseminated tumor cells. Cell Signal (2011) 1.08
Comparative evaluation of urokinase-type plasminogen activator receptor expression in primary breast carcinomas and on metastatic tumor cells. Int J Cancer (2003) 1.08
Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J Clin Oncol (2008) 1.07
Dual roles of the transcription factor grainyhead-like 2 (GRHL2) in breast cancer. J Biol Chem (2013) 1.07
Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res (2009) 1.06
Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. PLoS One (2012) 1.06
Methyl-CpG binding domain proteins and their involvement in the regulation of the MAGE-A1, MAGE-A2, MAGE-A3, and MAGE-A12 gene promoters. Mol Cancer Res (2007) 1.05
Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 promotes progression of non-small cell lung cancer. Clin Cancer Res (2003) 1.05